Jn Biosciences LLC

Biograph 55, Inc.

Abmuno Therapeutics LLC

Igm Biosciences, Inc.

Regimmune Corporation

Omar Duramad

Nils Lonberg

Naoya Tsurushita

J Yun Tso

Paul Tumeh

Leonard G Presta

Yasuyuki Ishii

Bruce Alan Keyt

Ramesh Baliga

Fen Zhang

Leonard Presta

Beatrice Tien-Yi Wang

Haruhiko Morita

Hidetoshi Akimoto

ANTI-CD19/ANTI-CD38 COMMON LIGHT CHAIN BISPECIFIC ANTIBODIES

The invention provides monoclonal antibodies that specifically bind to TIGIT. The monoclonal antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The monoclonal antibodies can be used for treatment of cancer and infectious disease, among other applications.

Antibodies to TIGIT

Provided are anti-CD19 and anti-CD38 common light chain bispecific antibodies. The anti-CD19 and anti-CD38 bispecific antibodies described herein are useful in methods for treating a cancer or a tumor.

Composite binding molecules targeting immunosuppressive B cells

This disclosure provides pentameric and hexameric CD20 binding molecules and methods of using such molecules to direct complement-mediated, T-cell-mediated, or both complement-mediated and T-cell-mediated killing of CD20-expressing cells.

Multimeric bispecific binding molecules specific for CD20 and CD3

The purpose of the present invention is to provide a preparation for preventing or treating type I diabetes, said preparation exerting an excellent effect of preventing or treating type I diabetes, and a method for preventing or treating type I diabetes. The onset and symptoms of type I diabetes can be very remarkably relieved by dosing a combination of: (A) at least one member selected from the group consisting of proinsulin, insulin, insulin A chain, insulin B chain, fragments thereof and variants thereof; with (B) &#x3b1;-GalCer.

Preparation for preventing or treating type I diabetes

Growing community of inventors

Berkeley, CA, United States of America

Omar Duramad